Treatment of Ventilator-Associated Pneumonia

  • J. Solé-Violán
  • F. Rodríguez de Castro
Part of the Perspectives on Critical Care Infectious Diseases book series (CCID, volume 4)

Abstract

Ventilator-associated pneumonia (VAP), is the most common infection documented in the Intensive Care Unit (ICU), with reported incidence rates of 10-30% depending on the type of ICU, the severity of illness of the study population and the diagnostic criteria used. (1,2). Crude mortality rate has ranged from 20 to 71%, (3) and debate persists about whether it is due to the infection itself or to the severe underlying illness (4,5). Indeed, the attributable mortality of VAP is questionable in some clinical settings, such as trauma patients or episodes of infections caused by primary endogenous pathogens (6). On the other hand, current data available indicate that the episodes caused by Pseudomonas aeruginosa,Acinetobacter baumanii or methicillin-resistant Staphylococcus aureus (MRSA), cause an excess of mortality compared with the predictions made on the basis of severity-ofillness on ICU admission.(7, 8, 9)

Keywords

Pneumonia Influenza Pseudomonas Vancomycin Cephalosporin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy and preventative strategies. A consensus statement. Am.1 Respir Crit Care Med. 1995;153:1711–1725.Google Scholar
  2. 2.
    Cunnion KM, Weber DJ, Broadhead WE, et al. Risk factors for nosocomial pneumonia: comparing adult critical care populations. Am J Respir Crit Care Med. 1996;154: 158–162.CrossRefGoogle Scholar
  3. 3.
    George DL. Epidemiology of nosocomial pneumonia in intensive care unit patients. Clin Chest Med. 1995;16:29–43.PubMedGoogle Scholar
  4. 4.
    Fagon JY, Chastre J, Vuagnat A, et al. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA. 1996;275:866–869CrossRefPubMedGoogle Scholar
  5. 5.
    Papazian L, Bregeon F, Thirion X, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med. 1997;154:91–97.CrossRefGoogle Scholar
  6. 6.
    Baker AM, Meredith JW, Haponik EF. Pneumonia in intubated trauma patients: microbiology and outcomes. Am J Respir Crit Care Med. 1996;153:343–349.CrossRefPubMedGoogle Scholar
  7. 7.
    Rello J, Jubert P, Artigas A, Rue M, Niederman MS. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis. 1996;23:973–978.CrossRefPubMedGoogle Scholar
  8. 8.
    Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med. 1994;150:1545–1549CrossRefPubMedGoogle Scholar
  9. 9.
    Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997;11:676–685.CrossRefGoogle Scholar
  10. 10.
    Alvarez-Lerma F and the ICU-Acquired Pneumonia Study Group. Modifications of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996;22:387–394.CrossRefGoogle Scholar
  11. 11.
    Rello J, Gallego M, Mariscal D, Sonora R, Vallés J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156:196–200.CrossRefPubMedGoogle Scholar
  12. 12.
    Kollef MH, Ward S. The influence of mini-BAL cultures on patients outcomes. Implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113:412–420.CrossRefPubMedGoogle Scholar
  13. 13.
    Fagon JY, Chastre, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture technique. Am Rev Respir Dis. 1989;139:877–884CrossRefPubMedGoogle Scholar
  14. 14.
    Solé Violán J, Rodríguez de Castro F, Rey A, Martín González J, Cabrera Navarro P. Usefulness of microscopic examination of intracellular organisms in lavage fluid in ventilator-associated pneumonia. Chest. 1994;106:889–894.CrossRefPubMedGoogle Scholar
  15. 15.
    Solé Violán J, Rodríguez de Castro F, Caminero Luna J, Bordes Benítez A, Manzano Alonso JL. Comparative efficacy of bronchoalveolar lavage and telescoping plugged catheter in the diagnosis of pneumonia in mechanically ventilated patients. Chest. 1993;103:386–390.CrossRefPubMedGoogle Scholar
  16. 16.
    Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle HD. Prevalence and diagnosis of Legionella pneumonia: a 3-year prospective study with emphasis on application of urinary antigen detection. J Infect Dis. 1990;162:1341–1348.CrossRefPubMedGoogle Scholar
  17. 17.
    Rello J, Torres A. Microbial causes of ventilator-associated pneumonia. Semin Respir Infect. 1996; 11:24–31.PubMedGoogle Scholar
  18. 18.
    Niederman MS, Craven DE, Fein AM, Schultz DE. Pneumonia in the critically ill hospitalized patient. Chest. 1990;97:170–181CrossRefPubMedGoogle Scholar
  19. 19.
    Chevret S, Hemmer M, Carlet J, Langer M. Incidence and risk factors of pneumonia acquired in intensive care units: results from a multicenter prospective study on 996 patients. Intensive Care Med. 1993;19:256–264.CrossRefPubMedGoogle Scholar
  20. 20.
    Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995;108:1655–1662.CrossRefPubMedGoogle Scholar
  21. 21.
    Rello J, Quintana E, Ausina V, et al. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis. 1990;142:1320–1324.CrossRefPubMedGoogle Scholar
  22. 22.
    Rello J, Ausina V, Ricart M, et al. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med. 1994;20:193–198.CrossRefPubMedGoogle Scholar
  23. 23.
    Talon D, Mulin B, Rouget C, et al. Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 1998;157:978–984.CrossRefPubMedGoogle Scholar
  24. 24.
    Rodriguez J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med. 1992;93:29–34.CrossRefGoogle Scholar
  25. 25.
    Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest. 1993;104:1230–1235.CrossRefPubMedGoogle Scholar
  26. 26.
    Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis. 1989;139:887–894.Google Scholar
  27. 27.
    Rello J. Acinetobacter baumanii infections in the ICU: customization is the key. Chest. 1999;115:1226–1229.CrossRefPubMedGoogle Scholar
  28. 28.
    Corbella X, Pujol M, Ayats J, et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumanii. Clin Infect Dis. 1996;23:329–334.CrossRefPubMedGoogle Scholar
  29. 29.
    Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Repir Crit Care Med. 1998;157:531–529.CrossRefGoogle Scholar
  30. 30.
    Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites. Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med. 1999;160:608–613.CrossRefPubMedGoogle Scholar
  31. 31.
    Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia. A prospective study. Chest. 1999;115:178–183.CrossRefPubMedGoogle Scholar
  32. 32.
    Vallés J, Rello J, Fernández R et al. Role of bronchoalveolar lavage in mechanically ventilated patients with suspected pneumonia. Eur J Clin Microbiol Infec Dis. 1994; 13:549–558.CrossRefGoogle Scholar
  33. 33.
    Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6:234–244.CrossRefPubMedGoogle Scholar
  34. 34.
    Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540–546.CrossRefPubMedGoogle Scholar
  35. 35.
    Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621–1629.CrossRefPubMedGoogle Scholar
  36. 36.
    Sieger B, Jon Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Crit Care Med 1997; 25:1663–1670.CrossRefPubMedGoogle Scholar
  37. 37.
    Brewer SC, Wunderink RG, Jones CB, Leeper KV. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109:1019–1029.CrossRefGoogle Scholar
  38. 38.
    Rodríguez de Castro F, Solé-Violán J, Aranda A, et al. Do quantitative cultures of protected brush specimens modify the initial empirical therapy in ventilated patients with suspected pneumonia?. Eur Respir J 1996; 9:37–41.CrossRefGoogle Scholar
  39. 39.
    Drusano GL, Goldstein FW. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Suppl A):141–154.CrossRefPubMedGoogle Scholar
  40. 40.
    Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta analysis. Ann Intern Med 1996;124:717–725.PubMedGoogle Scholar
  41. 41.
    Craig WA. Pharmacokinetic/Pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1–12.CrossRefPubMedGoogle Scholar
  42. 42.
    Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547–557.CrossRefPubMedGoogle Scholar
  43. 43.
    Mukhopadhyay S, Singh M, Cater JI, et al. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364–368.CrossRefPubMedGoogle Scholar
  44. 44.
    Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303–316.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • J. Solé-Violán
    • 1
  • F. Rodríguez de Castro
    • 1
  1. 1.Hospital Universitario de Gran CanariaLas Palmas de GCSpain

Personalised recommendations